SUBSCRIBE: Print / eNewsletter
The associate professor at The Ohio State University Comprehensive Cancer Center discussed the implications of her analysis of the CAR T-cell therapy tisagenlecleucel for patients with diffuse large B-cell lymphoma at the ASH Annual Meeting & Exposition.
Lori Leslie, MD, talks about the developments of chimeric antigen receptor T-cell therapy and its impact on diffuse large B-cell lymphoma at the ASH Annual Meeting and Exposition.
Andre H. Goy, MD, MS, from Hackensack University Medical Center, discussed ways to address the extension of survival for patients with DLBCL who achieved a complete remission at the ASH Annual Meeting & Exposition.
The Swedish Cancer Center expert discussed the addition of polatuzumab vedotin to a bendamustine-rituximab regimen at the ASH Annual Meeting & Exposition.
The ZUMA-II trial suggested that patients with relapsed/refractory mantle cell lymphoma resistant to prior therapies may benefit from the autologous anti-CD19 CAR T-cell therapy.
Matthew S. Davids, MD, MMSc, discussed his phase I/II study of duvalisib combined with venetoclax for patients with relapsed/refractory CLL and SLL at the ASH Annual Meeting & Exposition.
Treatment with lenalidomide and rituximab improved progression-free survival, compared with placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma.
Lisocabtagene maraleucel induced high response rates in patients with aggressive relapsed/refractory large B-cell lymphoma.
The combination use of polatuzumab-vedotin, obinutuzumab, and lenalidomide showed high complete response rates in patients with relapsed/refractory follicular lymphoma.
The CAR T-cell therapy axicabtagene ciloleucel induced a median overall survival of 25.8 months for patients with refractory large B-cell lymphoma.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
